Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...
A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...
Serious adverse events occurred in 51.2 and 21.9% of patients receiving melphalan/hepatic delivery system and BAC, respectively. HealthDay News — For patients with unresectable metastatic uveal ...
Hepatic adenoma is an uncommon, benign liver tumor. Benign means that it’s not cancerous. It’s also known as hepatocellular adenoma or liver cell adenoma. Hepatic adenoma is extremely rare. It most ...
Melphalan/HDS treatment for patients with hepatic dominant metastatic uveal melanoma: Results from an expanded access program.
THE liver acts as a selective barrier between the gastrointestinal tract and the systemic circulation, metabolizing, detoxifying and elaborating for further physiologic disposition various substances ...
By recreating a fetal liver niche, FLOs show how liver and immune cells co-develop. Learn more about new groundbreaking ...
Congenital hepatic fibrosis is a type of liver disease that is present from birth. It typically affects the function of the bile ducts and the veins that carry blood from the digestive tract to the ...
LIVERS and alcohol do not get on well together. That is well known. But precisely how alcohol destroys the liver of someone who drinks too much has been a mystery. Though alcohol (technically, ethanol ...
Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback